Eli Lilly Gene Therapy Restores Deaf Child’s Hearing
Hearing loss is a prevalent sensory condition that affects millions of people worldwide. Despite its prevalence, there are currently no approved pharmacologic treatments for this condition. However, recent advancements in gene therapy have brought a glimmer of hope to individuals with hearing loss. In an extraordinary breakthrough, Eli Lilly & Co., a leading pharmaceutical company, has successfully restored the hearing of a child born deaf using an experimental gene therapy called AK-OTOF. This groundbreaking therapy targets the otoferlin gene mutations responsible for a specific form of hearing loss.
AK-OTOF is a novel gene therapy developed by Eli Lilly & Co. and acquired through their subsidiary, Akouos Inc. This therapy utilizes a dual adeno-associated viral vector-based gen...